Home › Kidney Cancer › NCT05842044
NSAID Use After Robotic Partial Nephrectomy
RecruitingPhase 2
NSAID Use After Robotic Partial Nephrectomy (No-PAIN): a Randomized, Controlled Trial
Who can join
Ages 18 to 99 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients undergoing uncomplicated robotic assisted laparoscopic partial nephrectomy for renal mass at the University of Miami Hospital and Network Sites (Deerfield Beach, Plantation, Lennar (Coral Gables), and Kendal). * Age 18-99. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Allergy to NSAIDs * Myocardial infarction or unstable angina within 12 months. * Any history of coronary artery bypass graft surgery. * History or active peptic ulcer disease, gastrointestinal (GI) bleeding, GI perforation. History of bleeding disorder. Glomerular filtration rate (GFR) \< 60 mL/min/1.73m2 (Modification of Diet in Renal Disease (MDRD) equation). * Taking any anti-platelet or anti-coagulation medications concurrently (e.g. warfarin, aspirin, clopidogrel, rivaroxaban etc.) * Chronic opioid use (use within 12 weeks) or history of opioid use disorder. * Solitary kidney. * Pregnancy. * Inability to give informed consent or unable to meet requirement of the study for any reason.
About the study
The purpose of this study is to see how effective non-steroidal anti-inflammatory drugs (NSAIDs) are at controlling pain without side effects in participants after robotic-assisted partial nephrectomy.
What is being tested
- Ketorolac (drug)
- Acetaminophen (drug)
- Oxycodone (drug)
- Hydromorphone (drug)
- Ibuprofen (drug)
Sponsor: University of Miami · Participants: 110 · Started: Sep 15, 2023
Contact the study team
- Mark L Gonzalgo, MD, PhD · Phone: 305-243-3246
Official record on ClinicalTrials.gov — NCT05842044
Locations in the U.S.
| Florida | University of Miami, Miami |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.